Alaunos Therapeutics Statistics
Total Valuation
TCRT has a market cap or net worth of $5.86 million. The enterprise value is $5.51 million.
Important Dates
The last earnings date was Friday, May 15, 2026, after market close.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRT has 2.42 million shares outstanding. The number of shares has increased by 27.10% in one year.
| Current Share Class | 2.42M |
| Shares Outstanding | 2.42M |
| Shares Change (YoY) | +27.10% |
| Shares Change (QoQ) | -16.23% |
| Owned by Insiders (%) | 21.07% |
| Owned by Institutions (%) | 9.02% |
| Float | 1.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,953.86 |
| Forward PS | n/a |
| PB Ratio | 4.47 |
| P/TBV Ratio | 4.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,835.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.63
| Current Ratio | 1.63 |
| Quick Ratio | 0.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -350.30% and return on invested capital (ROIC) is -220.85%.
| Return on Equity (ROE) | -350.30% |
| Return on Assets (ROA) | -129.43% |
| Return on Invested Capital (ROIC) | -220.85% |
| Return on Capital Employed (ROCE) | -321.82% |
| Weighted Average Cost of Capital (WACC) | -1.94% |
| Revenue Per Employee | $3,000 |
| Profits Per Employee | -$4.22M |
| Employee Count | 1 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.72% in the last 52 weeks. The beta is -1.13, so TCRT's price volatility has been lower than the market average.
| Beta (5Y) | -1.13 |
| 52-Week Price Change | -4.72% |
| 50-Day Moving Average | 2.80 |
| 200-Day Moving Average | 2.88 |
| Relative Strength Index (RSI) | 36.06 |
| Average Volume (20 Days) | 11,370 |
Short Selling Information
The latest short interest is 8,714, so 0.36% of the outstanding shares have been sold short.
| Short Interest | 8,714 |
| Short Previous Month | 12,380 |
| Short % of Shares Out | 0.36% |
| Short % of Float | 0.46% |
| Short Ratio (days to cover) | 0.49 |
Income Statement
In the last 12 months, TCRT had revenue of $3,000 and -$4.22 million in losses. Loss per share was -$2.07.
| Revenue | 3,000 |
| Gross Profit | -1.44M |
| Operating Income | -4.14M |
| Pretax Income | -4.11M |
| Net Income | -4.22M |
| EBITDA | -4.13M |
| EBIT | -4.14M |
| Loss Per Share | -$2.07 |
Full Income StatementBalance Sheet
The company has $354,000 in cash and n/a in debt, with a net cash position of $354,000 or $0.15 per share.
| Cash & Cash Equivalents | 354,000 |
| Total Debt | n/a |
| Net Cash | 354,000 |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | 1.29M |
| Book Value Per Share | 0.54 |
| Working Capital | 375,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.13 million and capital expenditures -$98,000, giving a free cash flow of -$3.23 million.
| Operating Cash Flow | -3.13M |
| Capital Expenditures | -98,000 |
| Depreciation & Amortization | 14,500 |
| Net Borrowing | n/a |
| Free Cash Flow | -3.23M |
| FCF Per Share | -$1.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -138,166.67% |
| Pretax Margin | -136,966.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.10% |
| Shareholder Yield | n/a |
| Earnings Yield | -71.91% |
| FCF Yield | -55.04% |
Analyst Forecast
The average price target for TCRT is $205.50, which is 8,391.74% higher than the current price. The consensus rating is "Hold".
| Price Target | $205.50 |
| Price Target Difference | 8,391.74% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 18, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 18, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
TCRT has an Altman Z-Score of -688.96 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -688.96 |
| Piotroski F-Score | 2 |
